Society of Thoracic Surgeons’ 2026 Guidelines for Postoperative Atrial Fibrillation: A Phase-Based, Multimodal Approach

© 2026 HMP Global. All Rights Reserved.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of EP Lab Digest or HMP Global, their employees, and affiliates. 

EP LAB DIGEST. 2026;26(3).

Interview by Jodie Elrod

In this exclusive interview, Subhasis Chatterjee, MD, and Stefano Schena, MD, PhD, discuss the Society of Thoracic Surgeons’ (STS) 2026 Clinical Practice Guidelines for the Prevention and Treatment of New-Onset Postoperative Atrial Fibrillation (POAF) After Cardiac Surgery. Dr Chatterjee is an Associate Professor of Surgery at the Baylor College of Medicine in Houston, Texas; Dr Schena is an Associate Professor of Surgery at the Medical College of Wisconsin in Milwaukee, Wisconsin.

What clinical need or gap in care do the STS 2026 guidelines aim to address in the prevention and management of new-onset POAF after cardiac surgery?

POAF remains the most common complication after cardiac surgery, affecting roughly 20% to 40% of patients. Despite this high incidence, the way it is prevented and managed has varied widely across institutions.

The goal of the STS 2026 guidelines is to bring a more consistent, evidence-based approach to this problem across each perioperative stage. Importantly, we wish for clinicians to move away from thinking of POAF management as a single intervention or a one-size-fits-all strategy. POAF following cardiac surgery is driven by multiple mechanisms—inflammation, atrial stretch, autonomic changes, and surgical factors—so the most effective strategy is a multimodal one that targets several of these pathways.

The guidelines highlight practical opportunities to intervene before, during, and after surgery.[SS1]  These include pharmacologic strategies such as prophylactic amiodarone, which has strong clinical evidence supporting its role in reducing POAF in appropriately selected patients. By aligning teams around a structured perioperative approach, we hope to reduce variability in care and ultimately reduce the incidence and consequences of POAF.

How does the phase-based approach—preoperative, intraoperative, and postoperative—change the way clinicians should think about preventing and treating POAF in everyday practice?

One of the key conceptual shifts in the guidelines is recognizing that POAF is not just a postoperative event. The risk begins before surgery, evolves during the operation, and manifests afterward.

The phase-based approach encourages clinicians to intervene across all 3 stages. Preoperatively, that means identifying high-risk patients and implementing preventive strategies such as amiodarone or beta-blocker [SC2] prophylaxis in patients, which has demonstrated a number needed to treat of 7 for reducing POAF. Intraoperatively, surgeons have important opportunities to reduce risk through operative techniques. One example highlighted in the guidelines is posterior pericardiotomy, which has been supported by multiple randomized trials as a simple maneuver that can reduce the incidence of POAF up to 50% by improving pericardial drainage and reducing pericardial inflammation potentially causing atrial irritability.

Postoperatively, the focus shifts to monitoring, early management of arrhythmia, and thoughtful decisions around rhythm control and anticoagulation. When you connect these phases together, POAF prevention becomes a coordinated perioperative strategy rather than a reactive response after the arrhythmia appears.

What is the most important takeaway for surgeons and care teams when applying these guidelines, particularly in areas where evidence remains limited or uncertain?

One of the most important messages in the guidelines relates to anticoagulation after POAF. The clinical data suggest that the benefits of anticoagulation in POAF are not as robust as they are in patients with chronic, nonsurgical AF.

There are certainly patients who should receive anticoagulation, particularly those with valve surgery or high stroke risk. But a blanket, aggressive anticoagulation strategy for all patients with POAF does not appear to be supported by the available data. This is an area that requires thoughtful clinical judgment, balancing stroke risk against bleeding risk in the early postoperative period.

The anticoagulation question also points to a larger opportunity: as we implement these guidelines across institutions, we have the chance to generate the real-world evidence that will refine future recommendations. Prospective registries tracking POAF burden, rhythm monitoring data, anticoagulation decisions, and stroke or bleeding outcomes will be critical. Advances in wearable cardiac monitors and AI-driven risk prediction tools may eventually allow us to identify which patients with brief, self-limited POAF can safely avoid anticoagulation and which require more aggressive therapy. For now, the guidelines emphasize that clinical judgment—informed by the best available evidence and shared decision-making with patients—remains essential when navigating areas of uncertainty

In summary, the 2026 guidelines provide a structured framework for POAF prevention and management while acknowledging that in areas of evolving evidence—particularly around anticoagulation—thoughtful clinical judgment and shared decision-making remain as important as any protocol.

The transcripts have been edited for clarity and length.